Skip to main content

Study title: A Randomized, Double-blind, Placebo-controlled, Multicenter Phase III Study of Olaparib Plus Abiraterone Relative to Placebo Plus Abiraterone as First-line Therapy in Men with Metastatic Castration-resistant Prostate Cancer

Clinical Trial Grant
Duke Scholars

Administered By

Duke Cancer Institute

Awarded By

AstraZeneca AB

Start Date

May 24, 2019

End Date

May 26, 2024
 

Administered By

Duke Cancer Institute

Awarded By

AstraZeneca AB

Start Date

May 24, 2019

End Date

May 26, 2024